La jolla Pharmaceutical

About:

La Jolla Pharmaceutical is a biopharmaceutical company that is focused on innovative therapeutics for chronic organ failure and cancer.

Website: https://www.lajollapharmaceutical.com

Description:

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. LJPC-501, the Company's second product candidate, is a natural peptide for the treatment of the hepatorenal syndrome.

Total Funding Amount:

$191M

Estimated Revenue Range:

$50M to $100M

Headquarters Location:

San Diego, California, United States

Founded Date:

1989-01-01

Contact Email:

medicalinformation(AT)ljpc.com

Founders:

Number of Employees:

101-250

Last Funding Date:

2015-09-09

IPO Status:

Public

Industries:

© 2025 bioDAO.ai